Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
25 06 2019
Historique:
received: 25 03 2019
accepted: 11 05 2019
entrez: 21 6 2019
pubmed: 21 6 2019
medline: 17 6 2020
Statut: ppublish

Résumé

Haplo-identical transplant with posttransplant cyclophosphamide (haplo) and umbilical cord blood transplant supported by third-party CD34 cells (haplo-cord) are competing approaches to alternative donor transplant. We compared, in adults younger than age 60 years, the outcomes of 170 haplo at 1 institution with that of 137 haplo-cord at 2 other institutions. All received reduced intensity conditioning with fludarabine and melphalan ± total body irradiation. GVHD prophylaxis for haplo consisted of cyclophosphamide, tacrolimus, and mycophenolate, whereas haplo-cord received antithymocyte globulin, tacrolimus, and mycophenolate. Haplo transplant used mostly bone marrow, and peripheral blood stem cells were used in haplo-cord transplants. Haplo-cord were older and had more advanced disease. Haplo-cord hastened median time to neutrophil (11 vs 18 days,

Identifiants

pubmed: 31217161
pii: bloodadvances.2019000200
doi: 10.1182/bloodadvances.2019000200
pmc: PMC6595267
doi:

Substances chimiques

Enzyme Inhibitors 0
Immunosuppressive Agents 0
Myeloablative Agonists 0
Cyclophosphamide 8N3DW7272P
Vidarabine FA2DM6879K
Mycophenolic Acid HU9DX48N0T
fludarabine P2K93U8740
Melphalan Q41OR9510P
Tacrolimus WM0HAQ4WNM

Banques de données

ClinicalTrials.gov
['NCT01810588', 'NCT01050946']

Types de publication

Clinical Trial Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1858-1867

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

© 2019 by The American Society of Hematology.

Références

Biol Blood Marrow Transplant. 2019 Jan;25(1):121-128
pubmed: 30205230
Biol Blood Marrow Transplant. 2009 May;15(5):564-73
pubmed: 19361748
Biol Blood Marrow Transplant. 2018 Sep;24(9):1774-1775
pubmed: 30016655
N Engl J Med. 2012 Dec 13;367(24):2305-15
pubmed: 23234514
Oncoimmunology. 2015 Mar 20;4(3):e974393
pubmed: 25949893
Biol Blood Marrow Transplant. 2017 Jun;23(6):965-970
pubmed: 28263918
Biol Blood Marrow Transplant. 2015 Oct;21(10):1839-45
pubmed: 26119367
Biol Blood Marrow Transplant. 2012 Dec;18(12):1835-44
pubmed: 22796535
Blood. 2007 Nov 15;110(10):3784-92
pubmed: 17671231
Leuk Lymphoma. 2013 Jun;54(6):1242-9
pubmed: 23088744
Leuk Lymphoma. 2019 Jul;60(7):1693-1696
pubmed: 30741059
Leuk Lymphoma. 2017 Feb;58(2):288-297
pubmed: 27333804
Bone Marrow Transplant. 2015 Sep;50(9):1227-34
pubmed: 26052909
Semin Hematol. 2016 Oct;53(4):257-266
pubmed: 27788764
Blood. 2017 Jan 5;129(1):30-37
pubmed: 27821503
Blood. 2011 Dec 8;118(24):6438-45
pubmed: 21976674
Bone Marrow Transplant. 2018 May;53(5):521-534
pubmed: 29335625
Bone Marrow Transplant. 2017 Aug;52(8):1138-1143
pubmed: 28346415
Transplantation. 2017 Jan;101(1):e34-e38
pubmed: 27764032
Bone Marrow Transplant. 2020 Dec;55(12):2298-2307
pubmed: 32518291
Biol Blood Marrow Transplant. 2015 Nov;21(11):1985-93
pubmed: 26238810
Blood. 2015 Aug 20;126(8):1033-40
pubmed: 26130705
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2509-14
pubmed: 22232664
N Engl J Med. 2016 Sep 8;375(10):944-53
pubmed: 27602666
Haematologica. 2016 May;101(5):634-43
pubmed: 26869630
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269
Leukemia. 2015 May;29(5):1143-52
pubmed: 25371177

Auteurs

Koen van Besien (K)

Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY.

Andrew Artz (A)

Department of Hematology and Oncology, University of Chicago, Chicago, IL; and.

Richard E Champlin (RE)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Danielle Guarneri (D)

Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY.

Michael R Bishop (MR)

Department of Hematology and Oncology, University of Chicago, Chicago, IL; and.

Julianne Chen (J)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Usama Gergis (U)

Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY.

Tsiporah Shore (T)

Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY.

Hongtao Liu (H)

Department of Hematology and Oncology, University of Chicago, Chicago, IL; and.

Gabriela Rondon (G)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Sebastian A Mayer (SA)

Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY.

Samer A Srour (SA)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Wendy Stock (W)

Department of Hematology and Oncology, University of Chicago, Chicago, IL; and.

Stefan O Ciurea (SO)

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH